

# Erick H Turner

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4082007/publications.pdf>

Version: 2024-02-01

78  
papers

8,127  
citations

109321

35  
h-index

76900

74  
g-index

79  
all docs

79  
docs citations

79  
times ranked

8675  
citing authors

#	ARTICLE	IF	CITATIONS
1	Selective publication of antidepressant trials and its influence on apparent efficacy: Updated comparisons and meta-analyses of newer versus older trials. PLoS Medicine, 2022, 19, e1003886.	8.4	31
2	An open science pathway for drug marketing authorization—Registered drug approval. PLoS Medicine, 2021, 18, e1003726.	8.4	12
3	Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder. The Cochrane Library, 2021, 2021, CD011612.	2.8	20
4	Reporting of drug trial funding sources and author financial conflicts of interest in Cochrane and non-Cochrane meta-analyses: a cross-sectional study. BMJ Open, 2020, 10, e035633.	1.9	8
5	Approval of esketamine for treatment-resistant depression — Author's reply. Lancet Psychiatry, the, 2020, 7, 236.	7.4	1
6	Reporting of financial conflicts of interest in meta-analyses of drug trials published in high-impact medical journals: comparison of results from 2017 to 2018 and 2009. Systematic Reviews, 2020, 9, 77.	5.3	11
7	Esketamine for treatment-resistant depression: seven concerns about efficacy and FDA approval. Lancet Psychiatry, the, 2019, 6, 977-979.	7.4	104
8	Healthcare Options for People Experiencing Depression (HOPE*D): the development and pilot testing of an encounter-based decision aid for use in primary care. BMJ Open, 2019, 9, e025375.	1.9	13
9	Hiding negative trials by pooling them: a secondary analysis of pooled-trials publication bias in FDA-registered antidepressant trials. Psychological Medicine, 2019, 49, 2020-2026.	4.5	25
10	Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet, The, 2018, 391, 1357-1366.	13.7	2,076
11	Antidepressants might work for people with major depression: where do we go from here?. Lancet Psychiatry, the, 2018, 5, 461-463.	7.4	23
12	Network meta-analysis of antidepressants — Authors' reply. Lancet, The, 2018, 392, 1012-1013.	13.7	3
13	Comparative Efficacy and Acceptability of 21 Antidepressant Drugs for the Acute Treatment of Adults With Major Depressive Disorder: A Systematic Review and Network Meta-Analysis. Focus (American) Tj ETQq1 1 0.784314 rgBT/Over	13.7	3
14	Financial Conflicts of Interest Among Oncologist Authors of Reports of Clinical Drug Trials. JAMA Oncology, 2018, 4, 1426.	7.1	52
15	You can now search FDA approval documents easily at <a href="http://fda.opentrials.net">fda.opentrials.net</a> . BMJ: British Medical Journal, 2017, 356, j677.	2.3	4
16	Spin in RCTs of anxiety medication with a positive primary outcome: a comparison of concerns expressed by the US FDA and in the published literature. BMJ Open, 2017, 7, e012886.	1.9	5
17	Reporting of Positive Results in Randomized Controlled Trials of Mindfulness-Based Mental Health Interventions. PLoS ONE, 2016, 11, e0153220.	2.5	80
18	Comparative efficacy and acceptability of first-generation and second-generation antidepressants in the acute treatment of major depression: protocol for a network meta-analysis. BMJ Open, 2016, 6, e010919.	1.9	139

#	ARTICLE	IF	CITATIONS
19	Bias in the reporting of harms in clinical trials of second-generation antidepressants for depression and anxiety: A meta-analysis. <i>European Neuropsychopharmacology</i> , 2016, 26, 1752-1759.	0.7	24
20	Influence of baseline severity on antidepressant efficacy for anxiety disorders: Meta-analysis and meta-regression. <i>British Journal of Psychiatry</i> , 2016, 208, 515-521.	2.8	34
21	Does Publication Bias Inflate the Apparent Efficacy of Psychological Treatment for Major Depressive Disorder? A Systematic Review and Meta-Analysis of US National Institutes of Health-Funded Trials. <i>PLoS ONE</i> , 2015, 10, e0137864.	2.5	153
22	Reporting Bias in Clinical Trials Investigating the Efficacy of Second-Generation Antidepressants in the Treatment of Anxiety Disorders. <i>JAMA Psychiatry</i> , 2015, 72, 500.	11.0	92
23	From the FDA, we still hear mostly thunderous silence. <i>BMJ, The</i> , 2015, 351, h3763.	6.0	0
24	WHAT IS THE THRESHOLD FOR A CLINICALLY RELEVANT EFFECT? THE CASE OF MAJOR DEPRESSIVE DISORDERS. <i>Depression and Anxiety</i> , 2014, 31, 374-378.	4.1	141
25	Comparison of psychotherapies for adult depression to pill placebo control groups: a meta-analysis. <i>Psychological Medicine</i> , 2014, 44, 685-695.	4.5	86
26	Author's Reply to Shrier: "Publication Bias, With a Focus on Psychiatry: Causes and Solutions" <i>CNS Drugs</i> , 2013, 27, 775-776.	5.9	0
27	Publication Bias, with a Focus on Psychiatry: Causes and Solutions. <i>CNS Drugs</i> , 2013, 27, 457-468.	5.9	52
28	How to access and process FDA drug approval packages for use in research. <i>BMJ, The</i> , 2013, 347, f5992-f5992.	6.0	38
29	Rethinking recommendations for screening for depression in primary care. <i>Cmaj</i> , 2012, 184, 413-418.	2.0	184
30	Publication Bias in Antipsychotic Trials: An Analysis of Efficacy Comparing the Published Literature to the US Food and Drug Administration Database. <i>PLoS Medicine</i> , 2012, 9, e1001189.	8.4	88
31	Re-rethinking the article by Thombs and colleagues: Figure 1: <i>Cmaj</i> , 2012, 184, 438.2-439.	2.0	2
32	Reporting of conflicts of interest from drug trials in Cochrane reviews: cross sectional study. <i>BMJ, The</i> , 2012, 345, e5155-e5155.	6.0	46
33	The Effect of Funding Source on Outcome Reporting Among Drug Trials. <i>Annals of Internal Medicine</i> , 2011, 154, 137.	3.9	1
34	Reporting of Conflicts of Interest in Meta-analyses of Trials of Pharmacological Treatments. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 1008.	7.4	121
35	Novel Treatment Strategies for Depression in Patients With Hepatitis C. <i>Psychosomatics</i> , 2010, 51, 357-358.	2.5	4
36	All the relevant data?. <i>BMJ: British Medical Journal</i> , 2010, 341, c6487-c6487.	2.3	5

#	ARTICLE	IF	CITATIONS
37	Novel Treatment Strategies for Depression in Patients With Hepatitis C. <i>Psychosomatics</i> , 2010, 51, 357-358.	2.5	2
38	Novel methods to deal with publication biases: secondary analysis of antidepressant trials in the FDA trial registry database and related journal publications. <i>BMJ: British Medical Journal</i> , 2009, 339, b2981-b2981.	2.3	149
39	Ranking antidepressants. <i>Lancet, The</i> , 2009, 373, 1760.	13.7	17
40	Selective Publication of Antidepressant Trials and Its Influence on Apparent Efficacy. <i>New England Journal of Medicine</i> , 2008, 358, 252-260.	27.0	2,141
41	Closing a Loophole in the FDA Amendments Act. <i>Science</i> , 2008, 322, 44-46.	12.6	11
42	Efficacy of antidepressants. <i>BMJ: British Medical Journal</i> , 2008, 336, 516-517.	2.3	58
43	Posting FDA New Drug Application Reviews. <i>JAMA - Journal of the American Medical Association</i> , 2007, 298, 859.	7.4	2
44	Serotonin a la carte: Supplementation with the serotonin precursor 5-hydroxytryptophan. , 2006, 109, 325-338.		266
45	Is It Always Unethical to Use a Placebo in a Clinical Trial?. <i>PLoS Medicine</i> , 2005, 2, e72.	8.4	28
46	Correction/Clarification about FDA Review Documents. <i>PLoS Medicine</i> , 2005, 2, e422.	8.4	4
47	5-Hydroxytryptophan plus SSRIs for interferon-induced depression: Synergistic mechanisms for normalizing synaptic serotonin. <i>Medical Hypotheses</i> , 2005, 65, 138-144.	1.5	38
48	A Taxpayer-Funded Clinical Trials Registry and Results Database. <i>PLoS Medicine</i> , 2004, 1, e60.	8.4	46
49	Strategies to Decrease Costs of Prescribing Selective Serotonin Reuptake Inhibitors at a VA Medical Center. <i>Psychiatric Services</i> , 2003, 54, 195-200.	2.0	17
50	Patients With Seasonal Affective Disorder Have Lower Odor Detection Thresholds Than Control Subjects. <i>Archives of General Psychiatry</i> , 2002, 59, 1119.	12.3	47
51	Double-Blind, Placebo-Controlled Study of Single-Dose Metergoline in Depressed Patients With Seasonal Affective Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2002, 22, 216-220.	1.4	21
52	A Circadian Signal of Change of Season in Patients With Seasonal Affective Disorder. <i>Archives of General Psychiatry</i> , 2001, 58, 1108.	12.3	246
53	Ultradian oscillations in cranial thermoregulation and electroencephalographic slow-wave activity during sleep are abnormal in humans with annual winter depression. <i>Brain Research</i> , 2000, 866, 152-167.	2.2	25
54	Monorhinal odor identification and depression scores in patients with seasonal affective disorder. <i>Journal of Affective Disorders</i> , 1999, 56, 27-35.	4.1	49

#	ARTICLE	IF	CITATIONS
55	Serotonin hypothesis of winter depression: behavioral and neuroendocrine effects of the 5-HT1A receptor partial agonist ipsapirone in patients with seasonal affective disorder and healthy control subjects. <i>Psychiatry Research</i> , 1999, 86, 9-28.	3.3	31
56	Gender differences in glycosylated hemoglobin levels in seasonal affective disorder patients and controls. <i>Comprehensive Psychiatry</i> , 1999, 40, 234-237.	3.1	2
57	The Effects of Seasons and Light Therapy on G Protein Levels in Mononuclear Leukocytes of Patients With Seasonal Affective Disorder. <i>Archives of General Psychiatry</i> , 1999, 56, 178.	12.3	44
58	Role of serotonin transporter promoter repeat length polymorphism (5-HTTLPR) in seasonality and seasonal affective disorder. <i>Molecular Psychiatry</i> , 1998, 3, 175-177.	7.9	167
59	Validation of the hypomania interview guide-seasonal affective disorder (HIGH-SAD) version in patients with rapid cycling bipolar disorder. , 1998, 8, 166-168.		3
60	Treatment of a Rapidly Cycling Bipolar Patient by Using Extended Bed Rest and Darkness to Stabilize the Timing and Duration of Sleep. <i>Biological Psychiatry</i> , 1998, 43, 822-828.	1.3	155
61	Greater Improvement in Summer Than With Light Treatment in Winter in Patients With Seasonal Affective Disorder. <i>American Journal of Psychiatry</i> , 1998, 155, 1614-1616.	7.2	19
62	Effects of Tryptophan Depletion vs Catecholamine Depletion in Patients With Seasonal Affective Disorder in Remission With Light Therapy. <i>Archives of General Psychiatry</i> , 1998, 55, 524.	12.3	143
63	Effects of Leuprolide-Induced Hypogonadism and Testosterone Replacement on Sleep, Melatonin, and Prolactin Secretion in Men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997, 82, 3203-3207.	3.6	39
64	Light visor maintenance of light box response. <i>American Journal of Psychiatry</i> , 1997, 154, 1172a-1172.	7.2	2
65	Seasonality and pituitary volume. <i>Psychiatry Research - Neuroimaging</i> , 1997, 74, 151-157.	1.8	32
66	Seasonal variation in core temperature regulation during sleep in patients with winter seasonal affective disorder. <i>Biological Psychiatry</i> , 1997, 42, 122-131.	1.3	31
67	Agreement between face-to-face and telephone-administered mood ratings in patients with rapid cycling bipolar disorder. <i>Psychiatry Research</i> , 1997, 71, 129-132.	3.3	20
68	Effects of Leuprolide-Induced Hypogonadism and Testosterone Replacement on Sleep, Melatonin, and Prolactin Secretion in Men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997, 82, 3203-3207.	3.6	15
69	Diurnal Variation in the Direction of Mood Switches in Patients With Rapid-Cycling Bipolar Disorder. <i>Journal of Clinical Psychiatry</i> , 1997, 58, 79-84.	2.2	33
70	Effects of Exogenous Melatonin Administration and Withdrawal in Five Patients With Rapid-Cycling Bipolar Disorder. <i>Journal of Clinical Psychiatry</i> , 1997, 58, 383-388.	2.2	75
71	Salivary and plasma measures of dim light melatonin onset (DLMO) in patients with rapid cycling bipolar disorder. <i>Biological Psychiatry</i> , 1996, 40, 731-735.	1.3	43
72	Two naturally occurring amino acid substitutions of the 5-HT2A receptor: Similar prevalence in patients with seasonal affective disorder and controls. <i>Biological Psychiatry</i> , 1996, 40, 1267-1272.	1.3	79

#	ARTICLE	IF	CITATIONS
73	Cognitive Performance in Seasonal Affective Disorder: Pattern Recognition and the Stroop Task. <i>Journal of Nervous and Mental Disease</i> , 1996, 184, 56-59.	1.0	17
74	Effect of Season and Light Treatment Upon Hot Flashes in a Perimenopausal SAD Patient. <i>Chronobiology International</i> , 1995, 12, 290-297.	2.0	5
75	Bimodal patterns of human melatonin secretion consistent with a two-oscillator model of regulation. <i>Neuroscience Letters</i> , 1995, 194, 105-108.	2.1	49
76	Platelet [ <sup>3</sup> H]paroxetine binding, 5-HT-stimulated Ca <sup>2+</sup> response, and 5-HT content in winter seasonal affective disorder. <i>Biological Psychiatry</i> , 1994, 36, 458-466.	1.3	35
77	A controlled trial of cyanocobalamin (Vitamin B12) in the treatment of winter seasonal affective disorder. <i>Journal of Affective Disorders</i> , 1994, 32, 197-200.	4.1	20
78	Three-year follow-up of older schizophrenics: Extrapyramidal syndromes, psychiatric symptoms, and ventricular brain ratio. <i>Biological Psychiatry</i> , 1991, 30, 913-926.	1.3	36